Relationship among insulinlike growth factor i concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: A population-based study

Menopause

Volumn 15, Issue 5, 2008, Pages 934-939

  Nabipour, Iraj ^a   Larijani, Bagher ^b   Beigi, Saeideh ^a   Jafari, Seyed Mojtaba ^a   Amiri, Mohammad ^a   Assadi, Majid ^a   Pazoki, Raha ^a   Amiri, Zahra ^a   Sanjdideh, Zahra ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; CrossLaps; Insulinlike growth factor; Menopause; Osteocalcin

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; SOMATOMEDIN C; BIOLOGICAL MARKER;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POPULATION RESEARCH; PROTEIN DEGRADATION; AGED; BLOOD; BODY MASS; BONE REMODELING; FEMUR NECK; IRAN; LUMBAR VERTEBRA; METHODOLOGY; MIDDLE AGED; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; POSTMENOPAUSE; RADIOGRAPHY; RISK FACTOR; WOMEN'S HEALTH;

ABSORPTIOMETRY, PHOTON; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; BONE REMODELING; FEMALE; FEMUR NECK; HUMANS; INSULIN-LIKE GROWTH FACTOR I; IRAN; LUMBAR VERTEBRAE; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; WOMEN'S HEALTH;

EID: 58249093759     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31816665a7     Document Type: Article

References (37)

1. Ueland T. GH-IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 2005;152:327-332.
2. LeRoith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis. Endocr Rev 2001;22:53-74.
3. Zofkova I. Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism. Physiol Res 2003;52:657-679.
4. Friedlander AL, Butterfield GE, Moynihan S, et al. One year of insulin-like growth factor I treatment dose not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 2001;86:1496-1503.
5. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997;12:1272-1279.
6. Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005;21:1015-1026.
7. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997;12:1272-1279.
8. Munoz-Torres M, Mezquita-Raya P, Lopez-Rodriguez F, Torres-Vela E, de Dios Luna J, Escobar-Jimenez F. The contribution of IGF-I to skeletal integrity in postmenopausal women. Clin Endocrinol (Oxf) 2001;55:759-766.
9. Landin-Wilhelmsen K, Wilhelmsen L, Bengtsson BA. Postmenopausal osteoporosis is more related to hormonal aberrations than to lifestyle factors. Clin Endocrinol (Oxf) 1999;51:387-394.
10. Kim JG, Shin CS, Choi YM, Moon SY, Kim SY, Lee JY. The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60. Clin Endocrinol (Oxf) 1999;51:301-307.
11. Nakaoka D, Sugimoto T, Kaji H, et al. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women. Osteoporos Int 2001;12:548-554.
12. Yamaguchi T, Kanatani M, Yamauchi M, et al. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int 2006;78:18-24.
13. Collins D, Woods A, Herd R, et al. Insulin-like growth factor-I and bone mineral density. Bone 1998;23:13-16.
14. Rudman D, Drinka PJ, Wilson CR, et al. Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men. Clin Endocrinol (Oxf) 1994;40:653-661.
15. Bennett AE, Wahner HW, Riggs BL, Hintz RL. Insulin-like growth factors I and II: aging and bone density in women. J Clin Endocrinol Metab 1984;59:701-704.
16. Lloyd ME, Hart DJ, Nandra D, et al. Relation between insulin-like growth factor-1 concentration, osteoarthritis, bone density, and fractures in the general population: the Chinford study. Ann Rheum Dis 1996;55:870-874.
17. Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J. Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf) 2001;55:101-106.
18. Langlois JA, Rosen CJ, Visser M, et al. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 1998;83:4257-4262.
19. Barrett-Connor E, Goodman-Gruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. J Bone Miner Res 1998;13:1343-1349.
20. Salminen H, Sääf M, Ringertz H, Strender LE. The role of IGF-I and IGFBP-1 status and secondary hyperparathyroidism in relation to osteoporosis in elderly Swedish women. Osteoporos Int 2007;19:201-209.
21. Larijani B, Moayyeri A, Keshtkar AA, et al. Peak bone mass of Iranian population: the Iranian Multicenter Osteoporosis Study. J Clin Densitom 2006;9:367-374.
22. Ravaglia G, Forti P, Maioli F, et al. Body composition, sex steroids, IGF-I, and bone mineral status in aging men. J Gerontol A Biol Sci Med Sci 2000;55:M516-M521.
23. Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-I and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000;355:898-899.
24. Vestergaard P, Hermann AP, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab 1999;84:2286-2290.
25. Donahue LR, Rosen CJ. Insulin-like growth factors and bone: the osteoporosis connection revisited. Proc Soc Exp Biol Med 1998;219:1-7.
26. Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995;17(2 Suppl):93S-98S.
27. Yakar S, Rosen CJ. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med 2003;228:245-252.
28. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999;96:7324-7329.
29. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002;110:771-781.
30. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996;17:333-368.
31. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res 1999;14:1182-1188.
32. Landin-Wilhelmsen K, Lundberg PA, Lappas G, Wilhelmsen L. Insulin-like growth factor I levels in healthy adults. Horm Res 2004;62(Suppl 1):8-16.
33. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 1993;77:1384-1387.
34. Grinspoon SK, Baum HB, Peterson S, Klibanski A. Effects of rhIGF-I administration on bone turnover during short-term fasting. J Clin Invest 1995;96:900-906.
35. Johansson AG, Lindh E, Blum WF, Kollerup G, Sørensen OH, Ljunghall S. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996;81:44-48.
36. Delmas PD, Estell R, Garnero P, Seibel MJ, Stapan J. A position paper on the use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11(Suppl 6):2-17.
37. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-1053.